Neurocrine falls after analysts say forecast for key drug 'conservative'

Neurocrine Biosciences

07/02/2025 15:16

** Shares of drugmaker Neurocrine Biosciences  NBIX.O 
decline about 15% to $128.54 
    ** Co forecasts sales of its drug Ingrezza in the range of
$2.5 bln to $2.6 bln for 2025, in line with analysts'
expectations of $2.55 bln - according to LSEG data 
        ** Ingrezza is approved for treating involuntary
movements in the face, tongue, or other body parts related to
Huntington's disease, a genetic brain disorder 
    ** At least two brokerages said that forecast for Ingrezza,
NBIX's only drug on the market, was conservative 
    ** "Conservative Ingrezza guidance can be due to 
competition pressure" - Brokerage H.C. Wainwright, referring to
rival drug Austedo from Teva Pharmaceuticals  TEVA.N  
    ** Worse-than-expected forecast may show slowing of growth
for Neurocrine's most consistent drug - BMO Capital Markets
    ** Co posted Q4 total sales of $627.7 mln, below analyst est
of $629 mln- LSEG data
    ** In 2024, NBIX rose 3%

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com))